Back to Search
FAIZ KABBINAVAR, MD
MD
Family Medicine Physician
NPI: 1801425301IndividualAccepts Medicare
Specialties, Licenses & Credentials
Family Medicine PhysicianPrimary
Family Medicine
Code: 207Q00000X
A188300(CA)
CMS Specialties
PrimaryFAMILY PRACTICE
Education
OTHER
Class of 2020
Research & Publications (20)
Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.
PMID 19064978·J Clin Oncol·2009
2-rct
Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer.
PMID 18776057·Oncologist·2008
3-trial
Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk.
PMID 18852492·Oncology·2008
8-other
Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
PMID 15867200·J Clin Oncol·2005
3-trial
Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
PMID 15738537·J Clin Oncol·2005
3-trial
Can inhibition of angiogenic pathways increase the efficacy of intravenous 5-fluorouracil-based regimens?
PMID 15479482·Clin Colorectal Cancer·2004
3-trial
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
PMID 12506171·J Clin Oncol·2003
3-trial
CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis.
PMID 19539328·J Urol·2009
8-other
Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma.
PMID 19124809·J Clin Oncol·2009
8-other
Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma.
PMID 19228721·Clin Cancer Res·2009
8-other
Presence of tumor necrosis is not a significant predictor of survival in clear cell renal cell carcinoma: higher prognostic accuracy of extent based rather than presence/absence classification.
PMID 19230920·J Urol·2009
8-other
Molecular signatures of localized clear cell renal cell carcinoma to predict disease-free survival after nephrectomy.
PMID 19240241·Cancer Epidemiol Biomarkers Prev·2009
8-other
Functional and oncological outcomes of partial nephrectomy of solitary kidneys.
PMID 19298974·J Urol·2009
8-other
Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival.
PMID 18671240·Cancer·2008
8-other
Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance.
PMID 18661529·Cancer·2008
3-trial
Tumor size does not predict risk of metastatic disease or prognosis of small renal cell carcinomas.
PMID 18343437·J Urol·2008
8-other
Angiogenesis and angiogenic inhibitors in renal cell carcinoma.
PMID 18366971·Curr Urol Rep·2008
6-review
Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm.
PMID 18410444·BJU Int·2008
5-case
Cancer-specific survival outcomes among patients treated during the cytokine era of kidney cancer (1989-2005): a benchmark for emerging targeted cancer therapies.
PMID 18823034·Cancer·2008
8-other
The chemokine receptor CXCR3 is an independent prognostic factor in patients with localized clear cell renal cell carcinoma.
PMID 17997430·J Urol·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2425 SAMARITAN DR
SAN JOSE, CA 95124 - Phone
- (408) 559-2011
Quick Facts
- NPI
- 1801425301
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 6
- Publications
- 20
Are you this provider?
Claim Your Profile